Pliant Therapeutics, Inc. - PLRX STOCK NEWS

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company, announced participation in virtual fireside chats at upcoming investor conferences. The Piper Sandler 33rd Annual Virtual Healthcare Conference will feature a pre-recorded chat on November 22, 2021, at 10:00am ET. The Evercore ISI 4th Annual HealthconX Conference will occur on November 30, 2021, at 3:30pm ET. Presentations can be accessed on Pliant's website, with audio available for 90 days post-event. Pliant is focused on developing therapies for fibrosis, including their lead candidate, PLN-74809.

Pliant Therapeutics (PLRX) released its third quarter 2021 financial results, showcasing productive progress in clinical trials. Positive interim data from the Phase 2a PET trial showed up to 98% αvβ6 target engagement in patients with idiopathic pulmonary fibrosis (IPF). Enrollment for ongoing trials INTEGRIS-IPF and INTEGRIS-PSC is on track, with topline data expected mid-2022. Research and development expenses rose to $21.1 million, contributing to a net loss of $27.0 million. The company maintains a robust cash position of $221.0 million, projected to sustain operations into 2023.

Pliant Therapeutics (Nasdaq: PLRX) announced that CEO Bernard Coulie will participate in a virtual fireside chat during Piper Sandler Lung Day on October 15, 2021, at 11:00 a.m. ET. This event will focus on the company's efforts in developing novel therapeutics for fibrosis, particularly its lead candidate, PLN-74809, which targets idiopathic pulmonary fibrosis and primary sclerosing cholangitis. A replay of the chat will be available on Pliant's website for 90 days post-event.

Pliant Therapeutics announced positive interim results from its Phase 2a trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF). The single-dose administration achieved up to 98% target engagement in the lungs, exceeding the predicted threshold for anti-fibrotic activity across all doses. The trial demonstrated a dose-dependent response and indicated that PLN-74809 targets fibrotic regions effectively. The ongoing trial aims to assess safety and pharmacokinetics, while the company anticipates future clinical outcomes based on these findings.

Pliant Therapeutics (Nasdaq: PLRX) plans to release interim clinical data from its Phase 2a PET imaging trial of PLN-74809 for idiopathic pulmonary fibrosis (IPF) on September 7, 2021. The company will host a conference call and webcast at 8:00 a.m. ET to discuss this update. PLN-74809 is an oral dual selective inhibitor of αvß6 and αvß1 integrins, currently in trials for IPF and primary sclerosing cholangitis (PSC), and has received Orphan Drug Designation for both indications.

Pliant Therapeutics, a clinical stage biotechnology company, announced its participation in two upcoming investor conferences. The Citi 16th Annual BioPharma Virtual Conference is set for September 8-9, 2021, where the management team will engage in one-on-one meetings. Following this, the Cantor 2021 Virtual Global Healthcare Conference will occur on September 29, 2021, featuring a presentation by CEO Bernard Coulie at 2:40 p.m. ET, along with additional one-on-one meetings. Pliant is focused on developing therapies for fibrosis, including its lead candidate for idiopathic pulmonary fibrosis and primary sclerosing cholangitis.

Pliant Therapeutics (Nasdaq: PLRX) provided an update showing progress in its Phase 1a trial for PLN-74809, with SAD cohorts up to 640 mg and MAD cohorts up to 320 mg completed without safety concerns. The Phase 2a trials for idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC) are on track for enrollment completion by late 2021 and early 2022, respectively. Financially, the company reported a net loss of $22.8 million for Q2 2021, up from $17.0 million the previous year, driven by increased R&D expenses. Cash reserves stand at $244 million, expected to fund operations into 2023.

Pliant Therapeutics, Inc. (Nasdaq: PLRX), a biotechnology company focused on fibrosis treatments, will participate in the 2021 BTIG Virtual Biotechnology Conference from August 9-10, 2021. The company's CEO, Bernard Coulie, will engage in a fireside chat on August 10 at 3:30 p.m. EST. Pliant's lead candidate, PLN-74809, is an oral therapy for idiopathic pulmonary fibrosis and primary sclerosing cholangitis, having received Orphan Drug Designation from the FDA. The company is also advancing treatments for nonalcoholic steatohepatitis through partnerships and has additional preclinical oncology and muscular dystrophy programs.

Pliant Therapeutics (PLRX) provided a corporate update and first quarter financial results on May 10, 2021. The company’s PLN-74809 Phase 2a trials in idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC) are on track for enrollment completion by late 2021 and first half of 2022, respectively. The trial aims to evaluate safety, tolerability, and pharmacokinetics. Q1 2021 reported a net loss of $22.9 million, a decline from a net income of $11 million in Q1 2020. As of March 31, 2021, cash reserves stood at $264.1 million, sufficient to support operations into 2023.